Persistent atrial fibrillation as a prognostic factor of outcome in patients with advanced heart failure

Kardiologia Polska

Volumn 64, Issue 8, 2006, Pages 777-783

  Wojtkowska, Izabela ^a,b   Sobkowicz, Bozena ^a   Musiał, Włodzimierz J ^a   Kozuch, Marcin ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Klinika Kardiologii   (Poland)

Author keywords

Atrial fibrillation; Chronic heart failure; Prognosis

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; EXERCISE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HOSPITAL READMISSION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SINUS RHYTHM;

EID: 33749456748     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rodeheffer RJ. Epidemiologia niewydolności serca. Medycyna po Dyplomie 2005; 14: 133-44.
2. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005; 365: 1877-89.
3. Ponikowski P. Jak poprawić rokowanie w niewydolności serca? J Am Coll Cardiol PL 2001; 2: 231-2.
4. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32: 695-703.
5. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991; 84: 40-8.
6. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001; 104: 2118-50.
7. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002; 144: 597-607.
8. Diagnostyka i leczenie przewlekłej niewydolności serca. Wytyczne postȩpowania Europejskiego Towarzystwa Kardiologicznego (European Society of Cardiology, ESC). Uaktualnienie 2005. Kardiol Pol 2005; 63: 509-43.
9. Henry WL, DeMaria A, Gramiak R, et al. Report of the American Society of Echocardiography Committee on Nomenclature and Standards in Two-dimensional Echocardiography. Circulation 1980; 62: 212-7.
10. Enright PL. The six-minute walk test. Respir Care 2003; 48: 783-5.
11. Stanisz A. Przystȩpny kurs statystyki w programie STATISTICA 5.0 PL. Vol. II. Statsoft, Kraków 2000.
12. Brugada P, Andries E. "Tachycardiomyopathy". The most frequently unrecognized cause of heart failure? Acta Cardiol 1993; 48: 165-9.
13. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
14. Franz MR, Karasik PL, Li C, et al. Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1997; 30: 1785-92.
15. Follath F. Causes of acute heart failure - acute de novo versus decompensated chronic heart failure. Presentation and outcome of acute heart failure in clinical practice 2005 - preliminary results of the Euro Heart Survey on Acute Heart Failure. ESC Congress 2005. Available on: http://webcasts.prous. com/ESC2005/
16. Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984; 53: 902-7.
17. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 2001; 22: 1318-27.
18. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32: 695-703.
19. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990; 65: 903-8.
20. Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87(6 Suppl.): VI102-10.
21. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283: 1295-302.
22. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-15.
23. Świa̧tecka G. Choroby serca u kobiet. Via Medica, Gdańsk 2001.